HSCS.NASDAQHeartsciences INC
10-Q: HeartSciences Inc. Reports Q3 2025 Results, Faces Going Concern Uncertainty
Sentiment:
Quarterly Report
HeartSciences Inc. reports its Q3 2025 results, highlighting ongoing efforts to obtain FDA clearance for its MyoVista wav ECG device and addressing concerns about its ability to continue as a going concern.
Capital raiseThe company is offering up to 4,285,714 Units, with each Unit consisting of one share of Series D Convertible Preferred Stock and one warrant to purchase one share of Common Stock at $3.50 per Unit, for a maximum offering amount of $15.0 million worth of Units.Management plans include raising capital through the sale of additional equity securities, debt, or strategic partnerships.
Worse than expectedThe company's financial results show a net loss and no revenue for the period.The company's management believes that current resources would be insufficient to fund operations for the next twelve months.The company's disclosure controls and procedures were not effective as of January 31, 2025 as a result of identified material weaknesses in its internal control over financial reporting.
Summary
- HeartSciences Inc. reported its financial results for the third quarter of fiscal year 2025, ended January 31, 2025.
- The company is focused on applying AI-based technology to ECG devices to improve their clinical usefulness.
- HeartSciences is developing the MyoVista wav ECG device and the MyoVista Insights Cloud Platform.
- The company is preparing for a 510(k) FDA submission for the MyoVista wav ECG in the first half of 2025.
- The company has incurred losses each year since inception and has negative cash flows from operations.
- As of January 31, 2025, the company had an accumulated deficit of $74.0 million.
- The company's management believes that current resources would be insufficient to fund operations for the next twelve months.
- Management plans include raising capital through the sale of additional equity securities, debt, or strategic partnerships.
- There were no revenues for the three and nine months ended January 31, 2025.
- Research and development expenses increased to $1.0 million and $3.5 million for the three and nine months ended January 31, 2025, respectively.
- Selling, general, and administrative expenses increased to approximately $1.3 million and $3.0 million for the three and nine months ended January 31, 2025, respectively.
- The company's net loss was $2.5 million for the quarter and $6.7 million for the nine-month period.
- As of January 31, 2025, the company had cash and cash equivalents of approximately $2.6 million.
- The company is offering up to 4,285,714 Units, with each Unit consisting of one share of Series D Convertible Preferred Stock and one warrant to purchase one share of Common Stock at $3.50 per Unit, for a maximum offering amount of $15.0 million worth of Units.
Sentiment
Score: 3
Explanation: The document presents a mixed picture. While there are positive developments regarding product development and potential FDA submission, the company's financial situation and going concern uncertainty weigh heavily on the overall sentiment.
Positives
- The company is preparing for a 510(k) FDA submission for the MyoVista wav ECG in the first half of 2025.
- The company has entered into license agreements with Mount Sinai to commercialize a range of AI-ECG algorithms.
- The company is developing the MyoVista Insights Cloud Platform to host AI-ECG algorithms.
Negatives
- The company has incurred losses each year since inception and has negative cash flows from operations.
- As of January 31, 2025, the company had an accumulated deficit of $74.0 million.
- The company's management believes that current resources would be insufficient to fund operations for the next twelve months.
- There were no revenues for the three and nine months ended January 31, 2025.
- The company's net loss was $2.5 million for the quarter and $6.7 million for the nine-month period.
- The company's disclosure controls and procedures were not effective as of January 31, 2025 as a result of identified material weaknesses in its internal control over financial reporting.
Risks
- The company's ability to continue as a going concern is uncertain.
- The company's future success is dependent upon receiving FDA clearances for its products.
- The company may require additional funding to support the sales launch of the MyoVista wav ECG device in the U.S., provide working capital, and support further R&D.
- The company's disclosure controls and procedures were not effective as of January 31, 2025 as a result of identified material weaknesses in its internal control over financial reporting.
- The FDA can delay, limit or deny clearance of a medical device for many reasons outside the Company's control which may involve substantial unforeseen costs.
Future Outlook
The company is aiming for a 510(k) FDA submission for the MyoVista wav ECG in the first half of 2025 and for the MyoVista Insights Cloud Platform and low ejection fraction algorithm in the second half of 2025. The company will need to continue to raise capital through the sale of additional equity securities, debt, or capital inflows from strategic partnerships.
Management Comments
- Management believes that current resources would be insufficient to fund operations for the next twelve months.
- Management plans include raising capital through the sale of additional equity securities, debt, or capital inflows from strategic partnerships.
Industry Context
The company operates in the medical technology industry, specifically focusing on cardiovascular diagnostic technology. The company is seeking to provide AI-ECG solutions in any care setting worldwide in a manner that best suits different providers, either via one of the millions of ECGs currently in clinical use or via its proprietary MyoVista wav ECG device.
Comparison to Industry Standards
- The document does not provide enough information to make a detailed comparison to industry standards.
- Without specific competitor data or industry benchmarks, a comprehensive assessment is not possible.
- The document mentions the United States Preventive Services Task Force evaluation of conventional ECG testing, suggesting a need for improved diagnostic capabilities, which HeartSciences aims to address.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Control Weaknesses | The company's disclosure controls and procedures were not effective as of January 31, 2025 as a result of identified material weaknesses in its internal control over financial reporting, including lack of proper approval processes, insufficient U.S. GAAP and SEC accounting resources, and insufficient staff to maintain optimal segregation of duties. | 2025-01-31 | The company is taking remedial steps to improve its internal controls over financial reporting, including establishing a more robust process related to review of complex accounting transactions, preparation of account reconciliations, and review of journal entries. |
Stakeholder Impact
- Shareholders face the risk of dilution from potential capital raises.
- Employees face uncertainty due to the company's going concern status.
- Customers may experience delays or disruptions if the company faces financial difficulties.
- Creditors face increased risk due to the company's financial situation.
Next Steps
- The company is preparing for a 510(k) FDA submission for the MyoVista wav ECG in the first half of 2025.
- The company is aiming for an FDA submission of its MyoVista Insights Cloud Platform and low ejection fraction algorithm in the second half of 2025.
- The company will need to continue to raise capital through the sale of additional equity securities, debt, or capital inflows from strategic partnerships.
Key Dates
| Date | Description |
|---|---|
| 2012-05-01 | Date of Myovista Devices and TwoThousandFourHunderedMyovistaDevices |
| 2013-04-3 | Date of Myovista Devices and TwoThousandFourHunderedMyovistaDevices |
| 2013-03-1 | Date of PurchaseAgreementAndRegistrationRightsAgreementMember |
| 2013-03-10 | Date of PurchaseAgreementAndRegistrationRightsAgreementMember |
| 2013-03-15 | Date of TwoThousandTwentyThreeEquityIncentivePlanMember |
| 2013-03-16 | Date of PurchaseAgreementAndRegistrationRightsAgreementMember |
| 2020-04-01 | Date of OneMillionNotesMember |
| 2020-04-3 | Date of OneMillionNotesMember |
| 2020-07-02 | Date of OneMillionNotesMember |
| 2020-09-04 | Date of OneMillionNotesMember |
| 2021-11-03 | Date of OneMillionNotesMember |
| 2022-05-01 | Date of OneMillionNotesMember |
| 2022-05-31 | Date of OneMillionNotesMember |
| 2022-06-28 | Date of SeriesCConvertiblePreferredStockMember |
| 2023-01-31 | Date of FrontRangeVenturesLlcMember |
| 2023-03-1 | Date of PurchaseAgreementAndRegistrationRightsAgreementMember |
| 2023-03-10 | Date of PurchaseAgreementAndRegistrationRightsAgreementMember |
| 2023-03-15 | Date of TwoThousandTwentyThreeEquityIncentivePlanMember |
| 2023-03-16 | Date of PurchaseAgreementAndRegistrationRightsAgreementMember |
| 2023-04-3 | Date of SeriesCConvertiblePreferredStockMember |
| 2023-05-01 | Date of ServiceBasedStockOptionMember |
| 2023-09-01 | Date of EquityDistributionAgreementMember |
| 2023-09-3 | Date of EquityDistributionAgreementMember |
| 2023-09-18 | Date of AtTheMarketOfferingMember |
| 2023-09-30 | Date of end of period |
| 2023-10-31 | Date of SeriesCConvertiblePreferredStockMember |
| 2023-11-01 | Date of SecuredConvertiblePromissoryNotesMember |
| 2023-11-3 | Date of EquityDistributionAgreementMember |
| 2023-11-9 | Date of MaximGroupLLCMember:EquityDistributionAgreementMember |
| 2023-11-16 | Date of JohnQAdamsMember |
| 2023-11-17 | Date of MaximGroupLLCMember:EquityDistributionAgreementMember |
| 2023-11-27 | Date of TwoThousandTwentyThreeEquityIncentivePlanMember |
| 2024-01-31 | Date of SecuredConvertiblePromissoryNotesMember |
| 2024-04-3 | Date of SeriesABCConvertiblePreferredStockMember |
| 2024-04-30 | Date of PerformanceBasedStockOptionMember |
| 2024-05-01 | Date of AtmFacilityMember |
| 2024-08-19 | Date of FrontRangeVenturesLlcMember |
| 2024-09-01 | Date of StreetervilleNoteMember |
| 2024-09-3 | Date of StreetervilleNoteMember |
| 2024-09-12 | Date of StreetervilleNoteMember |
| 2024-09-30 | Date of end of period |
| 2024-10-17 | Effective date of corporate name change to HeartSciences Inc. |
| 2024-10-31 | Date of end of period |
| 2024-11-01 | Date of InitialPublicOfferingEquityLineAndThirdPartyMember |
| 2024-12-01 | Date of end of period |
| 2024-12-31 | Date of end of period |
| 2025-01-31 | End of the quarterly period |
| 2025-03-1 | Date of SeriesDConvertiblePreferredStockMember |
| 2025-03-10 | Date of MaximumMember |
| 2025-03-12 | Date of SubsequentEventMember |
| 2025-03-13 | Date of report |
| 2025-03-14 | Date of PurchaseAgreementAndRegistrationRightsAgreementMember |
| 2025-05-01 | Date of TwoThousandTwentyThreeEquityIncentivePlanMember |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.